The biopharmaceutical company will allow the US government to utilise its stocks of remdesivir, following the FDA’s approval to use the drug to treat COVID-19 cases.
This month, CEO Today had the pleasure to connect with Roel Bulthuis - the Managing Director of M Ventures (previously MS Ventures). The company is the strategic venture capital fund of Merck, which Roel established in 2009. M Ventures’ objective is to invest in innovative technologies and products with the potential to significantly impact Merck‘s […]
CEO Today Online and CEO Today magazine are dedicated to providing CEOs and C-level executives with the latest corporate developments, business news and technological innovations.
